The Alpha Synuclein pipeline drugs market research report outlays comprehensive information on the Alpha Synuclein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Alpha Synuclein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Metabolic Disorders, Cardiovascular, and Ophthalmology which include the indications Parkinson’s Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Type 2 Diabetes, Amyloidosis, Stroke, Acute Ischemic Stroke, and Glaucoma. It also reviews key players involved in Alpha Synuclein targeted therapeutics development with respective active and dormant or discontinued products.
The Alpha Synuclein pipeline targets constitutes close to 88 molecules. Out of which, approximately 73 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 11, 5, 1, 36, and 19 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 12, and 3 molecule.
Alpha Synuclein overview
Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.
For a complete picture of Alpha Synuclein’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
